{"id":341431,"date":"2025-08-20T14:54:10","date_gmt":"2025-08-20T14:54:10","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-exact-sciences-corporation\/"},"modified":"2025-08-20T14:54:10","modified_gmt":"2025-08-20T14:54:10","slug":"how-to-buy-exact-sciences-corporation","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/","title":{"rendered":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-341431","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Exact Sciences Corporation (EXAS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve g\u00fc\u00e7l\u00fc 2025 b\u00fcy\u00fcme potansiyeline sahip bu yenilik\u00e7i kanser tarama \u015firketindeki yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Exact Sciences Corporation (EXAS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve g\u00fc\u00e7l\u00fc 2025 b\u00fcy\u00fcme potansiyeline sahip bu yenilik\u00e7i kanser tarama \u015firketindeki yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin."},"intro":"Hayat kurtaran ve ayn\u0131 zamanda servetinizi b\u00fcy\u00fctme potansiyeline sahip bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Exact Sciences Corporation (EXAS), sa\u011fl\u0131k inovasyonu ile yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. Hastal\u0131klar\u0131 erken tespit etme \u015feklimizi de\u011fi\u015ftiren \u00e7\u0131\u011f\u0131r a\u00e7an kanser tarama teknolojisiyle, bu sadece ba\u015fka bir hisse senedi de\u011fil\u2014t\u0131bbi tarihin bir par\u00e7as\u0131 olma ve finansal gelece\u011finizi in\u015fa etme \u015fans\u0131d\u0131r. EXAS'\u0131n neden dikkatinizi hak etti\u011fini ve nas\u0131l hissedar olabilece\u011finizi birlikte ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Hayat kurtaran ve ayn\u0131 zamanda servetinizi b\u00fcy\u00fctme potansiyeline sahip bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Exact Sciences Corporation (EXAS), sa\u011fl\u0131k inovasyonu ile yat\u0131r\u0131m f\u0131rsat\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor. Hastal\u0131klar\u0131 erken tespit etme \u015feklimizi de\u011fi\u015ftiren \u00e7\u0131\u011f\u0131r a\u00e7an kanser tarama teknolojisiyle, bu sadece ba\u015fka bir hisse senedi de\u011fil\u2014t\u0131bbi tarihin bir par\u00e7as\u0131 olma ve finansal gelece\u011finizi in\u015fa etme \u015fans\u0131d\u0131r. EXAS'\u0131n neden dikkatinizi hak etti\u011fini ve nas\u0131l hissedar olabilece\u011finizi birlikte ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Hareketi<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla Exact Sciences Corporation (EXAS) <strong>45,68 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu, ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in hem f\u0131rsat hem de dikkat gerektiren kritik bir seviye. Bu fiyat noktas\u0131, yak\u0131n destek seviyelerinin hemen \u00fczerinde ancak analist hedeflerinin olduk\u00e7a alt\u0131nda yer al\u0131yor ve bir\u00e7ok ki\u015fi taraf\u0131ndan cazip bir giri\u015f penceresi olarak g\u00f6r\u00fcl\u00fcyor.<\/p> <p><strong>Takviminize not edin: 4 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck kataliz\u00f6r\u00fcn\u00fcz olacak. EXAS o tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarih bize g\u00f6steriyor ki, bu a\u00e7\u0131klamalar fiyat\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirebilir. \u015eirketin son kazan\u00e7 raporu 6 A\u011fustos 2025'te gelir beklentilerini a\u015fmalar\u0131 ve tam y\u0131l rehberli\u011fini y\u00fckseltmeleri sonras\u0131 etkileyici bir \u015fekilde %11,2 fiyat art\u0131\u015f\u0131 tetikledi.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>Ge\u00e7mi\u015f kazan\u00e7lar\u0131n bu hisseyi nas\u0131l hareket ettirdi\u011fine bakal\u0131m:<\/p> <table> <thead> <tr> <th>Tarih<\/th> <th>Olay<\/th> <th>Haber \u00d6ncesi Fiyat<\/th> <th>Haber Sonras\u0131 De\u011fi\u015fim<\/th> <th>\u00d6nemli Nokta<\/th> <\/tr> <\/thead> <tbody> <tr> <td>6 A\u011fu 2025<\/td> <td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td> <td>~41,00 $<\/td> <td>+%11,2<\/td> <td>Gelir a\u015f\u0131m\u0131 + rehberlik y\u00fckseltmesi<\/td> <\/tr> <tr> <td>May\u0131s 2024<\/td> <td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td> <td>52,50 $<\/td> <td>-%8,2<\/td> <td>K\u00e2r marj\u0131 beklentileri kar\u015f\u0131lanmad\u0131<\/td> <\/tr> <tr> <td>\u015eub 2025<\/td> <td>Y\u0131ll\u0131k Rehberlik<\/td> <td>48,75 $<\/td> <td>+%6,8<\/td> <td>G\u00fc\u00e7l\u00fc 2025 g\u00f6r\u00fcn\u00fcm\u00fc<\/td> <\/tr> <tr> <td>Kas 2024<\/td> <td>\u00dcr\u00fcn Lansman\u0131<\/td> <td>45,20 $<\/td> <td>+%4,3<\/td> <td>Cologuard Plus duyurusu<\/td> <\/tr> <tr> <td>A\u011fu 2024<\/td> <td>Medicare Kazan\u0131m\u0131<\/td> <td>43,80 $<\/td> <td>+%9,1<\/td> <td>Kapsam geni\u015fletme haberi<\/td> <\/tr> <\/tbody> <\/table> <p>Desen a\u00e7\u0131k: \u00fcr\u00fcn onaylar\u0131, Medicare kapsam\u0131 ve kazan\u00e7 a\u015f\u0131m\u0131 etraf\u0131ndaki olumlu s\u00fcrprizler \u00f6nemli yukar\u0131 y\u00f6nl\u00fc ivme yarat\u0131yor. A\u011fustos 2025 tepkisi, bu t\u00fcr olaylar etraf\u0131nda giri\u015f zamanlamas\u0131n\u0131n neden \u00f6nemli oldu\u011funu g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2> <p>EXAS, Mart'tan A\u011fustos 2025'e yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131, ancak bu karma\u015fan\u0131n bir y\u00f6ntemi var:<\/p> <p><strong>Mart 2025<\/strong>: Hisse %8,69 d\u00fc\u015f\u00fc\u015fle 42,06-50,17 $ aral\u0131\u011f\u0131nda dalgaland\u0131. Sa\u011fl\u0131k d\u00fczenlemeleriyle ilgili piyasa belirsizli\u011fi ba\u015f engeldi.<\/p> <p><strong>Nisan 2025<\/strong>: %5,43 art\u0131\u015fla toparlanma ba\u015flad\u0131, 39,97-46,48 $ aral\u0131\u011f\u0131nda istikrar sa\u011fland\u0131; yat\u0131r\u0131mc\u0131lar a\u015f\u0131r\u0131 sat\u0131m ko\u015fullar\u0131n\u0131 fark etti.<\/p> <p><strong>May\u0131s 2025<\/strong>: Patlay\u0131c\u0131 b\u00fcy\u00fcme! EXAS %23,31 art\u0131\u015fla en iyi ay\u0131n\u0131 ya\u015fad\u0131, 58,68 $ seviyesine ula\u015ft\u0131; \u015firket Cologuard\u2122 Plus'\u0131 piyasaya s\u00fcrd\u00fc ve \u00f6nemli ortakl\u0131klar kurdu.<\/p> <p><strong>Haziran 2025<\/strong>: B\u00fcy\u00fck y\u00fckseli\u015f sonras\u0131 kar realizasyonu ile %5,58 do\u011fal geri \u00e7ekilme, 50,09-57,40 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc.<\/p> <p><strong>Temmuz 2025<\/strong>: Daha geni\u015f piyasa volatilitesi i\u00e7inde %6,44 d\u00fc\u015f\u00fc\u015fle konsolidasyon devam etti, aral\u0131k: 48,19-55,90 $.<\/p> <p><strong>A\u011fustos 2025 (bug\u00fcne kadar)<\/strong>: \u015eu anda 45,68 $ seviyesinde, 2. \u00e7eyrek kazan\u00e7 art\u0131\u015f\u0131 sonras\u0131 dayan\u0131kl\u0131l\u0131k g\u00f6steriyor ve ard\u0131ndan istikrar sa\u011flad\u0131.<\/p> <p>Genel alt\u0131 ayl\u0131k trend, genellikle daha b\u00fcy\u00fck hareketlerden \u00f6nce gelen klasik bir \"toparlanma-konsolidasyon\" modeli g\u00f6steriyor. Hisse, 42-46 $ seviyelerinde birka\u00e7 kez sa\u011flam bir zemin buldu; bu da bu fiyatlarda g\u00fc\u00e7l\u00fc kurumsal destek oldu\u011funu g\u00f6steriyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket geli\u015fmelerine dayanarak, yol haritas\u0131 \u015f\u00f6yle g\u00f6r\u00fcn\u00fcyor:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 58-62 $ \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br> Neden? Gelir rehberli\u011finin 3,13-3,17 milyar $'a y\u00fckseltilmesi, Oncodetect\u2122 i\u00e7in Medicare kapsam\u0131n\u0131n geni\u015fletilmesi ve Freenome ortakl\u0131\u011f\u0131 birden fazla b\u00fcy\u00fcme motoru yarat\u0131yor.<\/p> <p><strong>2026 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 63-68 $<br> Cologuard Plus'\u0131n benimsenmesinin devam\u0131 ve uluslararas\u0131 geni\u015fleme %15-20 gelir b\u00fcy\u00fcmesini desteklemeli.<\/p> <p><strong>2028 Projeksiyonu<\/strong>: 75-85 $<br> Bu noktada kan bazl\u0131 kanser taramas\u0131 yayg\u0131nla\u015fabilir ve EXAS'\u0131n ilk hareket avantaj\u0131 getirilerini verebilir.<\/p> <p><strong>2030 Vizyonu<\/strong>: 90-110 $<br> S\u0131v\u0131 biyopsi pazar\u0131n\u0131n tahmini 13 milyar $'a ula\u015fmas\u0131 durumunda (<a href=\"https:\/\/financhill.com\/blog\/investing\/exact-sciences-stock-forecast\">sekt\u00f6r projeksiyonlar\u0131<\/a>), EXAS \u00f6nemli pazar pay\u0131 yakalayabilir.<\/p> <p>Ortalama analist hedefi 66,43 $ olup mevcut seviyelerden <strong>%45 yukar\u0131 potansiyel<\/strong> anlam\u0131na geliyor\u2014sa\u011fl\u0131k sekt\u00f6r\u00fcndeki en y\u00fckseklerden biri. 21 analist \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi verirken hi\u00e7 \"Sat\" \u00f6nerisi yok; profesyonel duyarl\u0131l\u0131k olduk\u00e7a olumlu.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Gitmeden \u00d6nce Bilin<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken B\u00fcy\u00fck Riskler:<\/h3> <ul> <li><strong>D\u00fczenleyici Rulet<\/strong>: FDA onaylar\u0131 biyotek hisse senetlerini yapabilir ya da bozabilir. Yeni \u00fcr\u00fcn onaylar\u0131nda ya\u015fanacak herhangi bir gecikme fiyat\u0131 h\u0131zla d\u00fc\u015f\u00fcrebilir.<\/li> <li><strong>Rekabetin Yo\u011funla\u015fmas\u0131<\/strong>: S\u0131v\u0131 biyopsi alan\u0131 kalabal\u0131kla\u015f\u0131yor. EXAS, Cologuard ile ilk hareket avantaj\u0131na sahip olsa da yeni girenler marjlar\u0131 a\u015f\u0131nd\u0131rabilir.<\/li> <li><strong>Geri \u00d6deme Riskleri<\/strong>: Medicare ve sigorta kapsam\u0131 de\u011fi\u015fiklikleri do\u011frudan geliri etkiler. Oncodetect\u2122 i\u00e7in yak\u0131n zamanda kazan\u0131lan Medicare kapsam\u0131 b\u00fcy\u00fck bir ba\u015far\u0131yd\u0131, ancak politika de\u011fi\u015fiklikleri olabilir.<\/li> <li><strong>Volatilite Ger\u00e7e\u011fi<\/strong>: Haftal\u0131k ortalama volatilite %5,5 (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-exas\/exact-sciences\">volatilite metrikleri<\/a>) ile bu, cesaret isteyen bir yat\u0131r\u0131m. G\u00fcnl\u00fck %3,8 dalgalanmalar dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131z\u0131 s\u0131nayabilir.<\/li> <li><strong>K\u00e2rl\u0131l\u0131k Zamanlamas\u0131<\/strong>: \u015eirket hen\u00fcz tutarl\u0131 \u015fekilde k\u00e2rl\u0131 de\u011fil (-5,45 $ EPS). B\u00fcy\u00fcme yat\u0131r\u0131m\u0131, nakit yakma d\u00f6nemlerinde sab\u0131r gerektirir.<\/li> <\/ul> <h3>Parlak Ye\u015fil I\u015f\u0131klar:<\/h3> <ul> <li><strong>Gelir Roketi<\/strong>: Y\u0131ll\u0131k %16 b\u00fcy\u00fcme, sa\u011fl\u0131k sekt\u00f6r\u00fcnde herhangi bir \u015firket i\u00e7in etkileyici.<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 G\u00fcc\u00fc<\/strong>: Cologuard Plus lansman\u0131, Oncodetect\u2122 Medicare kapsam\u0131 ve Freenome ortakl\u0131\u011f\u0131 birden fazla gelir ak\u0131\u015f\u0131 yarat\u0131yor.<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Kanser tarama talebi, n\u00fcfus ya\u015fland\u0131k\u00e7a ve fark\u0131ndal\u0131k artt\u0131k\u00e7a katlanarak b\u00fcy\u00fcyor.<\/li> <li><strong>Analist Sevgi Festivali<\/strong>: 21 \"G\u00fc\u00e7l\u00fc Al\" derecelendirmesi ve 90 $'a kadar hedefler? Biyoteknolojide nadir g\u00f6r\u00fclen bir konsens\u00fcs.<\/li> <li><strong>Tan\u0131n\u0131rl\u0131k Do\u011frulamas\u0131<\/strong>: 2025 Gallup Ola\u011fan\u00fcst\u00fc \u0130\u015f Yeri \u00d6d\u00fcl\u00fc ve Great Place To Work sertifikas\u0131, g\u00fc\u00e7l\u00fc y\u00f6netim ve k\u00fclt\u00fcr\u00fc g\u00f6steriyor\u2014genellikle g\u00f6z ard\u0131 edilir ama uzun vadeli ba\u015far\u0131 i\u00e7in kritik.<\/li> <\/ul> <h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <p>T\u00fcm verileri analiz ettikten sonra, \u015fu anda mant\u0131kl\u0131 olanlar \u015funlar:<\/p> <ol> <li><strong>Dolar Maliyet Ortalamas\u0131 Yap\u0131n<\/strong>: Volatilite nedeniyle, tek seferde b\u00fcy\u00fck yat\u0131r\u0131m yapmak yerine haftal\u0131k sabit miktarlarda yat\u0131r\u0131m yap\u0131n. Bu, giri\u015f noktalar\u0131n\u0131 dengeler.<\/li> <li><strong>Kazan\u00e7 Takvimi Uyar\u0131s\u0131<\/strong>: 4 Kas\u0131m i\u00e7in bildirim ayarlay\u0131n. Tarihsel olarak, g\u00fc\u00e7l\u00fc rehberlik oldu\u011funda kazan\u00e7 \u00f6ncesi al\u0131m EXAS i\u00e7in iyi sonu\u00e7 verdi.<\/li> <li><strong>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc Ak\u0131ll\u0131ca Belirleyin<\/strong>: T\u00fcm sermayenizi yat\u0131rmay\u0131n. Biyoteknoloji, \u00e7e\u015fitlendirilmi\u015f portf\u00f6y\u00fcn en fazla %5-10'u olmal\u0131.<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"EXAS ticareti, t\u0131bbi test sonu\u00e7lar\u0131n\u0131 beklemek gibidir\u2014sinir bozucu ama potansiyel olarak hayat de\u011fi\u015ftiren haberler. Fiyat g\u00fcncellemeleri aras\u0131nda nefes almay\u0131 unutmay\u0131n!\"<\/li> <\/ol> <h2>\u2705 Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Bu Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Platformunuzu Se\u00e7in<\/td> <td>Makul \u00fccretlerle NASDAQ eri\u015fimi sunan bir arac\u0131 kurum se\u00e7in<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesab\u0131 Fonlay\u0131n<\/td> <td>%20 dalgalanmay\u0131 g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>\"EXAS\" Aramas\u0131 Yap\u0131n<\/td> <td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Emir T\u00fcr\u00fc Se\u00e7imi<\/td> <td>Bu volatil hisse i\u00e7in giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek ad\u0131na limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130\u015flem ve Onay<\/td> <td>\u00dccretleri g\u00f6zden ge\u00e7irin\u2014toplam i\u015flem maliyetinin %1'in alt\u0131nda olmas\u0131na dikkat edin<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option EXAS Yat\u0131r\u0131m\u0131 \u0130\u00e7in Neden Mant\u0131kl\u0131?<\/h2> <p>Exact Sciences gibi yenilik\u00e7i \u015firketlerde pozisyon olu\u015fturmak isteyenler i\u00e7in Pocket Option, sa\u011fl\u0131k hissesi yat\u0131r\u0131m\u0131yla m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, EXAS pozisyonunuzu a\u015f\u0131r\u0131 sermaye taahh\u00fcd\u00fc olmadan kademeli olarak olu\u015fturabilirsiniz.<\/li> <li><strong>H\u0131zl\u0131 Hesap Kurulumu<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci sayesinde, EXAS'\u0131n s\u0131k haber kaynakl\u0131 fiyat hareketlerinden h\u0131zl\u0131ca faydalanabilirsiniz.<\/li> <li><strong>\u00c7e\u015fitli Fonlama Se\u00e7enekleri<\/strong>: 100'den fazla para \u00e7ekme y\u00f6ntemi, ba\u015far\u0131l\u0131 EXAS i\u015flemlerinden elde etti\u011finiz k\u00e2rlar\u0131 tercih etti\u011finiz \u00f6deme kanal\u0131yla alman\u0131z\u0131 sa\u011flar.<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyotek volatilitesine al\u0131\u015fmaya \u00e7al\u0131\u015fan yeni yat\u0131r\u0131mc\u0131lar i\u00e7in EXAS'\u0131n bazen vah\u015fi fiyat dalgalanmalar\u0131n\u0131 takip etmeyi \u00e7ok daha y\u00f6netilebilir k\u0131lar.<\/p> <h2>\ud83c\udfe5 2025'te Exact Sciences: Kanser Tarama Devrimi<\/h2> <p>Exact Sciences sadece ba\u015fka bir sa\u011fl\u0131k \u015firketi de\u011fil\u2014kanser tespiti devriminin \u00f6nc\u00fcs\u00fcd\u00fcr. \u015eirketin Cologuard testi, milyonlarca ki\u015fiyi kolorektal kanser i\u00e7in tarad\u0131 ve erken tespitle hayat kurtard\u0131.<\/p> <p>Mevcut piyasa konumu: EXAS, d\u0131\u015fk\u0131 bazl\u0131 DNA testi pazar\u0131nda lider konumda olup, A\u011fustos 2025'te duyurulan \u00f6zel Freenome ortakl\u0131\u011f\u0131yla kan bazl\u0131 taramaya geni\u015fliyor. Temmuz 2025'te Oncodetect\u2122 Molek\u00fcler Rezid\u00fcel Hastal\u0131k Testi i\u00e7in Medicare kapsam\u0131 sa\u011flanmas\u0131yla, \u015firket art\u0131k birden fazla gelir ak\u0131\u015f\u0131n\u0131 ayn\u0131 anda \u00e7al\u0131\u015ft\u0131r\u0131yor.<\/p> <p><strong>\u0130lgin\u00e7 2025 Ger\u00e7e\u011fi<\/strong>: Exact Sciences merkez ofisi, kanser tespiti inovasyonuna o kadar odakland\u0131 ki, \u00e7al\u0131\u015fanlar\u0131n katlar aras\u0131nda \u00e7\u00f6z\u00fcm \u00fcretmesi i\u00e7in \"fikir asans\u00f6rleri\" kurdu. \u015eimdiye kadarki en yarat\u0131c\u0131 fikir? Asans\u00f6r konu\u015fma kal\u0131plar\u0131n\u0131 yapay zeka ile analiz ederek beklenmedik tan\u0131sal i\u00e7g\u00f6r\u00fcler elde etmek!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Hareketi<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla Exact Sciences Corporation (EXAS) <strong>45,68 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu, ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in hem f\u0131rsat hem de dikkat gerektiren kritik bir seviye. Bu fiyat noktas\u0131, yak\u0131n destek seviyelerinin hemen \u00fczerinde ancak analist hedeflerinin olduk\u00e7a alt\u0131nda yer al\u0131yor ve bir\u00e7ok ki\u015fi taraf\u0131ndan cazip bir giri\u015f penceresi olarak g\u00f6r\u00fcl\u00fcyor.<\/p>\n<p><strong>Takviminize not edin: 4 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck kataliz\u00f6r\u00fcn\u00fcz olacak. EXAS o tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarih bize g\u00f6steriyor ki, bu a\u00e7\u0131klamalar fiyat\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirebilir. \u015eirketin son kazan\u00e7 raporu 6 A\u011fustos 2025&#8217;te gelir beklentilerini a\u015fmalar\u0131 ve tam y\u0131l rehberli\u011fini y\u00fckseltmeleri sonras\u0131 etkileyici bir \u015fekilde %11,2 fiyat art\u0131\u015f\u0131 tetikledi.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>Ge\u00e7mi\u015f kazan\u00e7lar\u0131n bu hisseyi nas\u0131l hareket ettirdi\u011fine bakal\u0131m:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<th>\u00d6nemli Nokta<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>6 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131<\/td>\n<td>~41,00 $<\/td>\n<td>+%11,2<\/td>\n<td>Gelir a\u015f\u0131m\u0131 + rehberlik y\u00fckseltmesi<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2024<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>52,50 $<\/td>\n<td>-%8,2<\/td>\n<td>K\u00e2r marj\u0131 beklentileri kar\u015f\u0131lanmad\u0131<\/td>\n<\/tr>\n<tr>\n<td>\u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Rehberlik<\/td>\n<td>48,75 $<\/td>\n<td>+%6,8<\/td>\n<td>G\u00fc\u00e7l\u00fc 2025 g\u00f6r\u00fcn\u00fcm\u00fc<\/td>\n<\/tr>\n<tr>\n<td>Kas 2024<\/td>\n<td>\u00dcr\u00fcn Lansman\u0131<\/td>\n<td>45,20 $<\/td>\n<td>+%4,3<\/td>\n<td>Cologuard Plus duyurusu<\/td>\n<\/tr>\n<tr>\n<td>A\u011fu 2024<\/td>\n<td>Medicare Kazan\u0131m\u0131<\/td>\n<td>43,80 $<\/td>\n<td>+%9,1<\/td>\n<td>Kapsam geni\u015fletme haberi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Desen a\u00e7\u0131k: \u00fcr\u00fcn onaylar\u0131, Medicare kapsam\u0131 ve kazan\u00e7 a\u015f\u0131m\u0131 etraf\u0131ndaki olumlu s\u00fcrprizler \u00f6nemli yukar\u0131 y\u00f6nl\u00fc ivme yarat\u0131yor. A\u011fustos 2025 tepkisi, bu t\u00fcr olaylar etraf\u0131nda giri\u015f zamanlamas\u0131n\u0131n neden \u00f6nemli oldu\u011funu g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2>\n<p>EXAS, Mart&#8217;tan A\u011fustos 2025&#8217;e yat\u0131r\u0131mc\u0131lar\u0131 olduk\u00e7a hareketli bir yolculu\u011fa \u00e7\u0131kard\u0131, ancak bu karma\u015fan\u0131n bir y\u00f6ntemi var:<\/p>\n<p><strong>Mart 2025<\/strong>: Hisse %8,69 d\u00fc\u015f\u00fc\u015fle 42,06-50,17 $ aral\u0131\u011f\u0131nda dalgaland\u0131. Sa\u011fl\u0131k d\u00fczenlemeleriyle ilgili piyasa belirsizli\u011fi ba\u015f engeldi.<\/p>\n<p><strong>Nisan 2025<\/strong>: %5,43 art\u0131\u015fla toparlanma ba\u015flad\u0131, 39,97-46,48 $ aral\u0131\u011f\u0131nda istikrar sa\u011fland\u0131; yat\u0131r\u0131mc\u0131lar a\u015f\u0131r\u0131 sat\u0131m ko\u015fullar\u0131n\u0131 fark etti.<\/p>\n<p><strong>May\u0131s 2025<\/strong>: Patlay\u0131c\u0131 b\u00fcy\u00fcme! EXAS %23,31 art\u0131\u015fla en iyi ay\u0131n\u0131 ya\u015fad\u0131, 58,68 $ seviyesine ula\u015ft\u0131; \u015firket Cologuard\u2122 Plus&#8217;\u0131 piyasaya s\u00fcrd\u00fc ve \u00f6nemli ortakl\u0131klar kurdu.<\/p>\n<p><strong>Haziran 2025<\/strong>: B\u00fcy\u00fck y\u00fckseli\u015f sonras\u0131 kar realizasyonu ile %5,58 do\u011fal geri \u00e7ekilme, 50,09-57,40 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc.<\/p>\n<p><strong>Temmuz 2025<\/strong>: Daha geni\u015f piyasa volatilitesi i\u00e7inde %6,44 d\u00fc\u015f\u00fc\u015fle konsolidasyon devam etti, aral\u0131k: 48,19-55,90 $.<\/p>\n<p><strong>A\u011fustos 2025 (bug\u00fcne kadar)<\/strong>: \u015eu anda 45,68 $ seviyesinde, 2. \u00e7eyrek kazan\u00e7 art\u0131\u015f\u0131 sonras\u0131 dayan\u0131kl\u0131l\u0131k g\u00f6steriyor ve ard\u0131ndan istikrar sa\u011flad\u0131.<\/p>\n<p>Genel alt\u0131 ayl\u0131k trend, genellikle daha b\u00fcy\u00fck hareketlerden \u00f6nce gelen klasik bir &#8220;toparlanma-konsolidasyon&#8221; modeli g\u00f6steriyor. Hisse, 42-46 $ seviyelerinde birka\u00e7 kez sa\u011flam bir zemin buldu; bu da bu fiyatlarda g\u00fc\u00e7l\u00fc kurumsal destek oldu\u011funu g\u00f6steriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Yolu<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve \u015firket geli\u015fmelerine dayanarak, yol haritas\u0131 \u015f\u00f6yle g\u00f6r\u00fcn\u00fcyor:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 58-62 $ \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> Neden? Gelir rehberli\u011finin 3,13-3,17 milyar $&#8217;a y\u00fckseltilmesi, Oncodetect\u2122 i\u00e7in Medicare kapsam\u0131n\u0131n geni\u015fletilmesi ve Freenome ortakl\u0131\u011f\u0131 birden fazla b\u00fcy\u00fcme motoru yarat\u0131yor.<\/p>\n<p><strong>2026 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 63-68 $<br \/> Cologuard Plus&#8217;\u0131n benimsenmesinin devam\u0131 ve uluslararas\u0131 geni\u015fleme %15-20 gelir b\u00fcy\u00fcmesini desteklemeli.<\/p>\n<p><strong>2028 Projeksiyonu<\/strong>: 75-85 $<br \/> Bu noktada kan bazl\u0131 kanser taramas\u0131 yayg\u0131nla\u015fabilir ve EXAS&#8217;\u0131n ilk hareket avantaj\u0131 getirilerini verebilir.<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 90-110 $<br \/> S\u0131v\u0131 biyopsi pazar\u0131n\u0131n tahmini 13 milyar $&#8217;a ula\u015fmas\u0131 durumunda (<a href=\"https:\/\/financhill.com\/blog\/investing\/exact-sciences-stock-forecast\">sekt\u00f6r projeksiyonlar\u0131<\/a>), EXAS \u00f6nemli pazar pay\u0131 yakalayabilir.<\/p>\n<p>Ortalama analist hedefi 66,43 $ olup mevcut seviyelerden <strong>%45 yukar\u0131 potansiyel<\/strong> anlam\u0131na geliyor\u2014sa\u011fl\u0131k sekt\u00f6r\u00fcndeki en y\u00fckseklerden biri. 21 analist &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi verirken hi\u00e7 &#8220;Sat&#8221; \u00f6nerisi yok; profesyonel duyarl\u0131l\u0131k olduk\u00e7a olumlu.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Gitmeden \u00d6nce Bilin<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken B\u00fcy\u00fck Riskler:<\/h3>\n<ul>\n<li><strong>D\u00fczenleyici Rulet<\/strong>: FDA onaylar\u0131 biyotek hisse senetlerini yapabilir ya da bozabilir. Yeni \u00fcr\u00fcn onaylar\u0131nda ya\u015fanacak herhangi bir gecikme fiyat\u0131 h\u0131zla d\u00fc\u015f\u00fcrebilir.<\/li>\n<li><strong>Rekabetin Yo\u011funla\u015fmas\u0131<\/strong>: S\u0131v\u0131 biyopsi alan\u0131 kalabal\u0131kla\u015f\u0131yor. EXAS, Cologuard ile ilk hareket avantaj\u0131na sahip olsa da yeni girenler marjlar\u0131 a\u015f\u0131nd\u0131rabilir.<\/li>\n<li><strong>Geri \u00d6deme Riskleri<\/strong>: Medicare ve sigorta kapsam\u0131 de\u011fi\u015fiklikleri do\u011frudan geliri etkiler. Oncodetect\u2122 i\u00e7in yak\u0131n zamanda kazan\u0131lan Medicare kapsam\u0131 b\u00fcy\u00fck bir ba\u015far\u0131yd\u0131, ancak politika de\u011fi\u015fiklikleri olabilir.<\/li>\n<li><strong>Volatilite Ger\u00e7e\u011fi<\/strong>: Haftal\u0131k ortalama volatilite %5,5 (<a href=\"https:\/\/simplywall.st\/stocks\/us\/pharmaceuticals-biotech\/nasdaq-exas\/exact-sciences\">volatilite metrikleri<\/a>) ile bu, cesaret isteyen bir yat\u0131r\u0131m. G\u00fcnl\u00fck %3,8 dalgalanmalar dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131z\u0131 s\u0131nayabilir.<\/li>\n<li><strong>K\u00e2rl\u0131l\u0131k Zamanlamas\u0131<\/strong>: \u015eirket hen\u00fcz tutarl\u0131 \u015fekilde k\u00e2rl\u0131 de\u011fil (-5,45 $ EPS). B\u00fcy\u00fcme yat\u0131r\u0131m\u0131, nakit yakma d\u00f6nemlerinde sab\u0131r gerektirir.<\/li>\n<\/ul>\n<h3>Parlak Ye\u015fil I\u015f\u0131klar:<\/h3>\n<ul>\n<li><strong>Gelir Roketi<\/strong>: Y\u0131ll\u0131k %16 b\u00fcy\u00fcme, sa\u011fl\u0131k sekt\u00f6r\u00fcnde herhangi bir \u015firket i\u00e7in etkileyici.<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 G\u00fcc\u00fc<\/strong>: Cologuard Plus lansman\u0131, Oncodetect\u2122 Medicare kapsam\u0131 ve Freenome ortakl\u0131\u011f\u0131 birden fazla gelir ak\u0131\u015f\u0131 yarat\u0131yor.<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Kanser tarama talebi, n\u00fcfus ya\u015fland\u0131k\u00e7a ve fark\u0131ndal\u0131k artt\u0131k\u00e7a katlanarak b\u00fcy\u00fcyor.<\/li>\n<li><strong>Analist Sevgi Festivali<\/strong>: 21 &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmesi ve 90 $&#8217;a kadar hedefler? Biyoteknolojide nadir g\u00f6r\u00fclen bir konsens\u00fcs.<\/li>\n<li><strong>Tan\u0131n\u0131rl\u0131k Do\u011frulamas\u0131<\/strong>: 2025 Gallup Ola\u011fan\u00fcst\u00fc \u0130\u015f Yeri \u00d6d\u00fcl\u00fc ve Great Place To Work sertifikas\u0131, g\u00fc\u00e7l\u00fc y\u00f6netim ve k\u00fclt\u00fcr\u00fc g\u00f6steriyor\u2014genellikle g\u00f6z ard\u0131 edilir ama uzun vadeli ba\u015far\u0131 i\u00e7in kritik.<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<p>T\u00fcm verileri analiz ettikten sonra, \u015fu anda mant\u0131kl\u0131 olanlar \u015funlar:<\/p>\n<ol>\n<li><strong>Dolar Maliyet Ortalamas\u0131 Yap\u0131n<\/strong>: Volatilite nedeniyle, tek seferde b\u00fcy\u00fck yat\u0131r\u0131m yapmak yerine haftal\u0131k sabit miktarlarda yat\u0131r\u0131m yap\u0131n. Bu, giri\u015f noktalar\u0131n\u0131 dengeler.<\/li>\n<li><strong>Kazan\u00e7 Takvimi Uyar\u0131s\u0131<\/strong>: 4 Kas\u0131m i\u00e7in bildirim ayarlay\u0131n. Tarihsel olarak, g\u00fc\u00e7l\u00fc rehberlik oldu\u011funda kazan\u00e7 \u00f6ncesi al\u0131m EXAS i\u00e7in iyi sonu\u00e7 verdi.<\/li>\n<li><strong>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc Ak\u0131ll\u0131ca Belirleyin<\/strong>: T\u00fcm sermayenizi yat\u0131rmay\u0131n. Biyoteknoloji, \u00e7e\u015fitlendirilmi\u015f portf\u00f6y\u00fcn en fazla %5-10&#8217;u olmal\u0131.<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;EXAS ticareti, t\u0131bbi test sonu\u00e7lar\u0131n\u0131 beklemek gibidir\u2014sinir bozucu ama potansiyel olarak hayat de\u011fi\u015ftiren haberler. Fiyat g\u00fcncellemeleri aras\u0131nda nefes almay\u0131 unutmay\u0131n!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Bu Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu Se\u00e7in<\/td>\n<td>Makul \u00fccretlerle NASDAQ eri\u015fimi sunan bir arac\u0131 kurum se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131 Fonlay\u0131n<\/td>\n<td>%20 dalgalanmay\u0131 g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;EXAS&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fc Se\u00e7imi<\/td>\n<td>Bu volatil hisse i\u00e7in giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek ad\u0131na limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130\u015flem ve Onay<\/td>\n<td>\u00dccretleri g\u00f6zden ge\u00e7irin\u2014toplam i\u015flem maliyetinin %1&#8217;in alt\u0131nda olmas\u0131na dikkat edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option EXAS Yat\u0131r\u0131m\u0131 \u0130\u00e7in Neden Mant\u0131kl\u0131?<\/h2>\n<p>Exact Sciences gibi yenilik\u00e7i \u015firketlerde pozisyon olu\u015fturmak isteyenler i\u00e7in Pocket Option, sa\u011fl\u0131k hissesi yat\u0131r\u0131m\u0131yla m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, EXAS pozisyonunuzu a\u015f\u0131r\u0131 sermaye taahh\u00fcd\u00fc olmadan kademeli olarak olu\u015fturabilirsiniz.<\/li>\n<li><strong>H\u0131zl\u0131 Hesap Kurulumu<\/strong>: 1 dakikal\u0131k KYC s\u00fcreci sayesinde, EXAS&#8217;\u0131n s\u0131k haber kaynakl\u0131 fiyat hareketlerinden h\u0131zl\u0131ca faydalanabilirsiniz.<\/li>\n<li><strong>\u00c7e\u015fitli Fonlama Se\u00e7enekleri<\/strong>: 100&#8217;den fazla para \u00e7ekme y\u00f6ntemi, ba\u015far\u0131l\u0131 EXAS i\u015flemlerinden elde etti\u011finiz k\u00e2rlar\u0131 tercih etti\u011finiz \u00f6deme kanal\u0131yla alman\u0131z\u0131 sa\u011flar.<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyotek volatilitesine al\u0131\u015fmaya \u00e7al\u0131\u015fan yeni yat\u0131r\u0131mc\u0131lar i\u00e7in EXAS&#8217;\u0131n bazen vah\u015fi fiyat dalgalanmalar\u0131n\u0131 takip etmeyi \u00e7ok daha y\u00f6netilebilir k\u0131lar.<\/p>\n<h2>\ud83c\udfe5 2025&#8217;te Exact Sciences: Kanser Tarama Devrimi<\/h2>\n<p>Exact Sciences sadece ba\u015fka bir sa\u011fl\u0131k \u015firketi de\u011fil\u2014kanser tespiti devriminin \u00f6nc\u00fcs\u00fcd\u00fcr. \u015eirketin Cologuard testi, milyonlarca ki\u015fiyi kolorektal kanser i\u00e7in tarad\u0131 ve erken tespitle hayat kurtard\u0131.<\/p>\n<p>Mevcut piyasa konumu: EXAS, d\u0131\u015fk\u0131 bazl\u0131 DNA testi pazar\u0131nda lider konumda olup, A\u011fustos 2025&#8217;te duyurulan \u00f6zel Freenome ortakl\u0131\u011f\u0131yla kan bazl\u0131 taramaya geni\u015fliyor. Temmuz 2025&#8217;te Oncodetect\u2122 Molek\u00fcler Rezid\u00fcel Hastal\u0131k Testi i\u00e7in Medicare kapsam\u0131 sa\u011flanmas\u0131yla, \u015firket art\u0131k birden fazla gelir ak\u0131\u015f\u0131n\u0131 ayn\u0131 anda \u00e7al\u0131\u015ft\u0131r\u0131yor.<\/p>\n<p><strong>\u0130lgin\u00e7 2025 Ger\u00e7e\u011fi<\/strong>: Exact Sciences merkez ofisi, kanser tespiti inovasyonuna o kadar odakland\u0131 ki, \u00e7al\u0131\u015fanlar\u0131n katlar aras\u0131nda \u00e7\u00f6z\u00fcm \u00fcretmesi i\u00e7in &#8220;fikir asans\u00f6rleri&#8221; kurdu. \u015eimdiye kadarki en yarat\u0131c\u0131 fikir? Asans\u00f6r konu\u015fma kal\u0131plar\u0131n\u0131 yapay zeka ile analiz ederek beklenmedik tan\u0131sal i\u00e7g\u00f6r\u00fcler elde etmek!<\/p>\n"},"faq":[{"question":"Exact Sciences Corporation (EXAS) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"EXAS hisseleri sat\u0131n almak i\u00e7in NASDAQ eri\u015fimi sunan bir arac\u0131 kurum se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"EXAS\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak i\u015flem yap\u0131n ve i\u015flem \u00fccretlerini kontrol edin."},{"question":"EXAS hisselerinin 2025-2030 fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 y\u0131l sonu hedefi 58-62 $ aral\u0131\u011f\u0131nda olup g\u00fc\u00e7l\u00fc al\u0131m \u00f6nerisi var. 2030 y\u0131l\u0131na kadar fiyat\u0131n 90-110 $ aras\u0131nda olmas\u0131 bekleniyor."},{"question":"EXAS yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"FDA onay gecikmeleri, artan rekabet, geri \u00f6deme politikalar\u0131ndaki de\u011fi\u015fiklikler, y\u00fcksek volatilite ve \u015firketin hen\u00fcz tutarl\u0131 k\u00e2rl\u0131l\u0131\u011fa ula\u015fmam\u0131\u015f olmas\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Pocket Option EXAS yat\u0131r\u0131m\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap a\u00e7ma, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile Pocket Option, EXAS gibi volatil sa\u011fl\u0131k hisseleri i\u00e7in ideal bir platformdur."},{"question":"EXAS'\u0131n kanser tarama alan\u0131ndaki yenilikleri nelerdir?","answer":"EXAS, milyonlarca ki\u015fiyi tarayan Cologuard testi ve kan bazl\u0131 tarama i\u00e7in Freenome ortakl\u0131\u011f\u0131 ile kanser tespitinde \u00f6nc\u00fc konumdad\u0131r. Ayr\u0131ca Oncodetect\u2122 testi i\u00e7in Medicare kapsam\u0131 alm\u0131\u015ft\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Exact Sciences Corporation (EXAS) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"EXAS hisseleri sat\u0131n almak i\u00e7in NASDAQ eri\u015fimi sunan bir arac\u0131 kurum se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"EXAS\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak i\u015flem yap\u0131n ve i\u015flem \u00fccretlerini kontrol edin."},{"question":"EXAS hisselerinin 2025-2030 fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 y\u0131l sonu hedefi 58-62 $ aral\u0131\u011f\u0131nda olup g\u00fc\u00e7l\u00fc al\u0131m \u00f6nerisi var. 2030 y\u0131l\u0131na kadar fiyat\u0131n 90-110 $ aras\u0131nda olmas\u0131 bekleniyor."},{"question":"EXAS yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"FDA onay gecikmeleri, artan rekabet, geri \u00f6deme politikalar\u0131ndaki de\u011fi\u015fiklikler, y\u00fcksek volatilite ve \u015firketin hen\u00fcz tutarl\u0131 k\u00e2rl\u0131l\u0131\u011fa ula\u015fmam\u0131\u015f olmas\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"Pocket Option EXAS yat\u0131r\u0131m\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap a\u00e7ma, \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile Pocket Option, EXAS gibi volatil sa\u011fl\u0131k hisseleri i\u00e7in ideal bir platformdur."},{"question":"EXAS'\u0131n kanser tarama alan\u0131ndaki yenilikleri nelerdir?","answer":"EXAS, milyonlarca ki\u015fiyi tarayan Cologuard testi ve kan bazl\u0131 tarama i\u00e7in Freenome ortakl\u0131\u011f\u0131 ile kanser tespitinde \u00f6nc\u00fc konumdad\u0131r. Ayr\u0131ca Oncodetect\u2122 testi i\u00e7in Medicare kapsam\u0131 alm\u0131\u015ft\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T14:54:10+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T14:54:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/\",\"name\":\"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-20T14:54:10+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/","og_locale":"tr_TR","og_type":"article","og_title":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T14:54:10+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T14:54:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/","name":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-20T14:54:10+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Exact Sciences Corporation (EXAS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exact Sciences Corporation (EXAS) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":341428,"slug":"how-to-buy-exact-sciences-corporation","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Exact Sciences Corporation (EXAS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Exact Sciences Corporation (EXAS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/"},"pt_AA":{"locale":"pt_AA","id":341432,"slug":"how-to-buy-exact-sciences-corporation","post_title":"Como comprar a\u00e7\u00f5es da Exact Sciences Corporation (EXAS) - Investimento em a\u00e7\u00f5es da Exact Sciences Corporation (EXAS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-exact-sciences-corporation\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=341431"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341431\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=341431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=341431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=341431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}